• 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Our present study was focused on the


    Our present study was focused on the clinical utility of tumor markers carcinoembryonic antigen (CEA), carbohydrate antigen (CA)-125, CA19-9, and CA72-4 in advanced stage of gas-tric cancer patients who had received palliative chemotherapy. We seek to measure whether
    Table 1
    Chemotherapy regimen for gastric carcinoma.
    First-line cisplatin palliative Dose and cycle chemotherapy
    these tumor biomarkers CEA, CA125, CA19-9, and CA72-4 can be of some value to monitor and predict the chemotherapeutic response and e cacy of 2-drugs (platinum-based chemotherapy alone) and 3-drugs (platinum-based chemotherapy plus antiangiogenic agents, ie, [Bevacizumab, Trastuzumab, Nitaluzumab, and Nidotuzumab]) in advanced stages of gastric cancer.
    Patients and methods
    The study was conducted at department of medical oncology, Jiangsu Cancer Hospital, Nan-jing, PR China, which was approved by the Research Ethics Committee on human research of Jiangsu Cancer Hospital. The medical records of 216 patients who underwent first-line chemotherapy from January 2014 to February 2018 at hospital were retrospectively studied. All the patients diagnosed and histologically confirmed with gastric cancer stage IV and had taken palliative chemotherapy were included in the study; Eastern Cooperative Oncology Group rou-tine investigation was 0-2. The Exclusion criteria for patients were those who had coexisting malignant neoplasm of an extra organ and those who had not follow up less than 4 cycles from the initial chemotherapy. All the data were collected until the progression of the tumor, death, or last medical fellow-up.
    The assessment to treat patients with palliative chemotherapy was made on the basis of their tumor histology and stage by specialists in gastric oncology, and also monitored that whether patients had the ability to tolerate therapy, and they Givinostat were treated in accordance with National Comprehensive Cancer Network guidelines.
    154 patients have taken first-line cisplatin chemotherapy palliative chemotherapy, ie, Irinote-can + Cisplatin, Irinotecan + Raltitrexed, Capecitabine + Irinotecan + Oxaliplatin, Oxaliplatin + 5-Fluorouracil, Capecitabine + Docetaxel, S-1 plus Oxaliplatin, Paclitaxel + 5-Fluorouracil, Peme-
    trexed + Oxaliplatin, Cisplatin + Fluorouracil (5FU), Docetaxel + Oxaliplatin, Irinotecan + Cisplatin, Paclitaxel + Oxaliplatin, Docetaxel + Oxaliplatin. While 62 patients have taken platinum- based chemotherapy plus antiangiogenic regimens palliative chemotherapy, ie, BEV + S1, Bevacizumab + Irinotecan, Nidotuzumab + Irinotecan + Cisplatin, Nidotuzumab + Paclitaxel, mFTP + Nidotuzumab, Nilaprozab + Oxaliplatin, Trastuzumab + Irinotecan + Raltitrexed 5 mg D1, Nitaluzumab + Docetaxel + Nedaplatin, Paclitaxel + Raltitrexed + Trastuzumab as mentioned in Tables 1 and 2.2,34-36
    Table 2
    Platinum-based chemotherapy plus antiangiogenic agents palliative chemotherapy-based regimens for patients.
    Platinum-based chemotherapy plus Dose and cycle
    anti-angiogenic regimens
    Bevacizumab + Irinotecan 21 d after 4-6 cycles are SOS box completed; continue until disease progression)
    Bevacizumab every 21 d after 4-6 cycles are completed; continue until
    Nidotuzumab + Irinotecan + Cisplatin disease progression)
    Nidotuzumab + Paclitaxel completed; continue until disease progression)
    nitoximab every 21 d after 4-6 cycles are completed; continue until
    mFTP + Nidotuzumab disease progression)
    mg D2 (continue Nidotuzumab every 21 d after 4-6 cycles are
    Nilaprozab + Oxaliplatin completed; continue until disease progression)
    every 21 d after 4-6 cycles are completed; continue until disease
    Trastuzumab + Irinotecan + Raltitrexed progression)
    (continue Trastuzumab every 21 d after 4-6 cycles are completed;
    Nitaluzumab + Docetaxel + Nedaplatin continue until disease progression)